Introduction
============

The role of genetic diagnostics in the evaluation of patients with Mendelian disorders is increasing rapidly in all fields of medicine. Understanding the underlying genetic causes of inherited diseases can contribute to the treatment and follow-up strategies, and may bring psychological comfort for the patient. Moreover, genetic diagnosis of the proband can allow effective risk assessment of family members, rationalize follow-up strategies, and enable earlier interventions.

Pulmonary arterial hypertension (PAH) is a severe and progressive disease characterized by vascular remodeling of small pulmonary arteries resulting in an increase in pulmonary arterial pressure, and eventually leading to right heart failure (Runo and Loyd [@b28]). Despite the improvement of treatments, PAH still remains a fatal disease with high mortality (Chakinala [@b5]). While the pathogenesis of idiopathic and hereditary forms of PAH (IPAH and HPAH) is a complex and incompletely understood, their genetic basis is well recognized. Hundreds of mutations in eight genes have been reported to associate with both IPAH and HPAH. HPAH is commonly regarded as an autosomal dominant disease (Larkin et al. [@b13]; Machado et al. [@b21]).

Mutations in the bone morphogenetic protein receptor 2 (*BMPR2*) gene, a member of the transforming growth factor beta (TGF-*β*) superfamily, are currently considered as main causes for the pathogenesis of PAH (Machado et al. [@b20]). Over 300 different *BMPR2* mutations have been identified in PAH patients (Machado et al. [@b21], [@b19]). Mutations in the *BMPR2* gene have been identified in up to 75% of HPAH cases and in 25% of IPAH cases. Previously, the penetrance of PAH among *BMPR2* mutation carriers was considered low, however, a recent study based on the Varderbilt Pulmonary Hypertension Registry found an overall penetrance of 27%, (42% in females and 14% in males). The disease penetrance could be even higher as the disease manifestation may be delayed for 75 years and express phenotypic variability (Larkin et al. [@b13]; Machado et al. [@b21]; Soubrier et al. [@b35]).

Other genes than *BMPR2* have been implicated in rare cases of PAH. Mutations in bone morphogenetic protein receptor 1B (*BMPR1B*), activin-like kinase-type 1 (*ACVRL1*; *ALK1*), endoglin (*ENG*), smad family member 9 (*SMAD9*), caveolin 1 (*CAV1*), potassium channel subfamily K, member 3 (*KCNK3*), and *NOTCH3* have been described in the development of the disease (Austin et al. [@b3]; Chaouat et al. [@b6]; Chida et al. [@b7]; Harrison et al. [@b11]; Li et al. [@b15]; Ma et al. [@b18]; Shintani et al. [@b33]). The role of these genes in the pathogenesis of IPAH and HPAH is suggested significantly smaller compared to *BMPR2*.

The genetic factors contributing to PAH in Finland, a genetic isolate in Europe, has not been comprehensively evaluated. In this study, we analyzed Finnish PAH patient isolate to detect pathogenic or likely pathogenic variants associated with PAH by utilizing the novel-targeted Oligonucleotide-Selective Sequencing (OS-Seq) technology (Myllykangas et al. [@b24]). We designed target-specific oligonucleotides to capture all coding exons, exon-intron boundaries, and known intronic mutations in the PAH-associated target genes. All these target genes were comprehensively analyzed using OS-Seq. These 21 Finnish PAH patients had been previously tested for mutations in the *BMPR2* and *ACVRL1* genes using Sanger sequencing (Sankelo et al. [@b30]). With OS-Seq we detected all previously identified pathogenic or likely pathogenic variants of *BMPR2* gene and identified two new pathogenic *BMPR2* variants that were previously missed using Sanger sequencing. Our results validate the use of OS-Seq panel for diagnostics of PAH.

Methods
=======

Patient samples
---------------

Blood samples for genetic studies were obtained from Finnish patients diagnosed with PAH under the approval from the Ethical Committees of the five University Hospitals and by the Ministry of Social Affairs and Health of Finland. All participants provided the written informed consent for genetic analysis as previously reported (Sankelo et al. [@b30]). Genomic DNA was extracted from the blood samples (Sankelo et al. [@b30]) and DNA samples of 21 Finnish iPAH (*N* = 18) and HPAH (*N* = 3) patients were selected for the study.

PAH panel
---------

Seven genes were selected for the PAH panel based on literature search in 2012-2013 (*BMPR2*, *BMPR1B*, *ACVRL1*, *ENG*, *SMAD9*, *CAV1*, and exon 2 of *KCNK3*) and all validated information about the mutations were incorporated into the bioinformatics pipeline (Table[1](#tbl1){ref-type="table"} and Fig.[1](#fig01){ref-type="fig"}). Noteworthy, exon 1 of *KCNK3* was omitted in the analysis because it is difficult to sequence due to extremely high GC content and because all mutations in *KCNK3* that have been linked with PAH are located in exon 2 (Ma et al. [@b18]).

###### 

Genes selected for diagnostics of PAH

  Gene symbol   Gene name                                  Reference
  ------------- ------------------------------------------ -----------------------------
  *BMPR2*       Bone morphogenic protein receptor 2        Machado et al. ([@b20])
  *BMPR1B*      Bone morphogenic protein receptor 1B       Chida et al. ([@b7], [@b8])
  *ACVRL1*      Activin A receptor type II like-1          Harrison et al. ([@b11])
  *ENG*         Endoglin                                   Chaouat et al. ([@b6])
  *SMAD9*       Smad family member 9                       Shintani et al. ([@b33])
  *CAV1*        Caveolin 1                                 Austin et al. ([@b3])
  *KCNK3*       Potassium channel, subfamily K, member 3   Ma et al. ([@b18])

![Distribution of mutations in genes selected for diagnostics of PAH. Mutations in seven PAH-associated genes were collected from the literature.](mgg30003-0354-f1){#fig01}

Sequencing
----------

The quality of genomic DNA samples was evaluated using gel electrophoresis and DNA concentration was measured using Qubit (Life Technologies, Grand Island, NY). Genomic DNA samples were fragmented using Fragmentase (New England Biolabs, Ipswitch, MA) and sequencing libraries were prepared using NEBNext Ultra (New England Biolabs) and PCR amplified. Target-specific oligonucleotides were designed to capture all coding exons, exon-intron boundaries, and known intronic mutations in the PAH-associated target genes and obtained from Integrated DNA Technologies (Leuven, Belgium). Exon definitions for target genes were derived from the CCDS. The targeting and sequencing of DNA was automated using the MiSeq Desktop Sequencer (Illumina, San Diego, CA). Pathogenic and likely pathogenic mutations found in the patient samples were confirmed using Sanger sequencing.

NGS data analysis
-----------------

Primary data analysis was carried out by Illumina's MiSeq Reporter software using the generateFASTQ workflow, that generates a single FASTQ file with base calls and Phred quality scores for R1 and R2 reads, separately. The data were transferred to a dedicated pipeline server for downstream analysis, which started with extraction of data for individual samples using a proprietary demultiplexing algorithm that analyses the 9 bp long index adapter sequence of each read to determine sample identity. Sequence reads were then trimmed to exclude adapter and capture oligo sequences using a proprietary algorithm that estimates the size of captured target DNA based on the genomic coordinates of read mate-pairs. Low-quality data were identified and removed using the Prinseq package (Schmieder and Edwards [@b31]) to exclude reads with more than 10% of unclassified nucleotides, as well as trimming nucleotides with Phred scores inferior to 20 from starting from the 3′- end. The cleaned-up sequence reads were subsequently aligned to the human reference sequence assembly GRCh37 using the Burrows-Wheeler Aligner (Li and Durbin [@b14]) in single-end mode with default parameters. Variant calling was performed using the Genome Analysis Tool Kit (GATK) (McKenna et al. [@b22]) following the guidelines outlined in the document "Best Practice Variant Detection with the GATK (v1.x)" issued by the developers.

Variant interpretation
----------------------

An automated bioinformatics pipeline was applied to identify pathogenic base substitutions, insertions and deletions (INDELs) in PAH-associated genes. Mutations that have been shown to be associated with PAH were collected from original research publications and existing mutation databases and queried using patients' variants. Population frequencies for detected variants were derived from the Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (<http://evs.gs.washington.edu/EVS>) and the Exome Aggregation Consortium (ExAC), Cambridge, MA (<http://exac.broadinstitute.org>). PolyPhen, SIFT (Adzhubei et al. [@b1]; Ng and Henikoff [@b25], [@b26]), and Mutation Taster (Schwarz et al. [@b32]) tools were used to predict the effects of variants on the protein structure and functions. Variants were classified as pathogenic or likely pathogenic when previous studies had identified them in other PAH patients. Furthermore, pathogenic gene variants associated with PAH are considered to be extremely rare or absent in control populations and often considered deleterious by in silico prediction.

Results
=======

Here, we present the first clinical study on Finnish PAH patients using the novel-targeted OS-Seq technology. We confirmed pathogenic or likely pathogenic variants of *BMPR2* in four patients and detected two new pathogenic variants of *BMPR2* gene that were previously missed using Sanger sequencing (Sankelo et al. [@b30]). Four out of six patients were carrying pathogenic gene variants that were predicted to cause a truncated BMPR2 protein: the point mutations c.994C\>T (p.Arg332X) in the kinase domain and c.1750C\>T (p.Arg584X) in the C-terminal cytoplasmic domain, and a deletion causing a frameshift mutation (c.1376_1377delGA, p.Arg459ThrfsX11) in the kinase domain in two patients. In addition, two of the patients had missense point mutations in *BMPR2*: c.1472G\>A (p.Arg491Gln) located in a kinase domain and c.2696G\>C (p.Arg899Pro) located in C-terminal cytoplasmic domain (Table[2](#tbl2){ref-type="table"}). Both of these variants featuring missense mutations were classified as deleterious in all in silico variant effect prediction analyses. In addition to these five pathogenic variants, three other variants were detected in *BMPR2*. Polymorphisms were observed in two patients and one short GGC-insertion in the promoter was identified in three patients (Table[3](#tbl3){ref-type="table"}). The clinical significance of the identified GGC-insertion is unknown, since the frequency of this variant is unknown in control populations, as the region is not covered in these databases. Altogether, our OS-Seq panel revealed six (29%) PAH patients carrying a pathogenic, or likely pathogenic, variant of *BMPR2* gene (Table[2](#tbl2){ref-type="table"}).

###### 

Mutations in *BMPR2* in Finnish iPAH and hPAH patients

  Patient                                    1               2                                           3               4                               5                  6
  ------------------------------------------ --------------- ------------------------------------------- --------------- ------------------------------- ------------------ -------------------------------
  Sex                                        F               F                                           M               M                               F                  F
  Age of diagnosis                           31              52                                          35              49                              19                 47
  Family history                             No              No                                          Yes             No                              No                 No
  Exon number                                8               10                                          11              12                              10                 12
  Nucleotide change                          c.994C\>T       c.1376_1377delGA                            c.1472G\>A      c.2696G\>C                      c.1376_1377delGA   c.1750C\>T
  Amino acid change                          p.Arg332X       p.Arg459ThrfsX11                            p.Arg491Gln     p.Arg899Pro                     p.Arg459ThrfsX11   p.Arg584X
  Mutation type                              Stop            Frameshift                                  Missense        Missense                        Frameshift         Stop
  Protein domain                             Kinase domain   Kinase domain                               Kinase domain   C-terminal cytoplasmic domain   Kinase domain      C-terminal cytoplasmic domain
  Detected previously by Sanger Sequencing   Yes             No                                          Yes             Yes                             Yes                No
  Mutation in other genes                    None            *ACVRL1*[\*](#tf2-2){ref-type="table-fn"}   None            None                            None               None

Likely benign (c.536A\>C, p.Asp179Ala). Mutation nomenclature is based on GenBank accession NM_001204.6 with nucleotide on being the first nucleotide of the translation initiation codon.

Refers to ^\*^ Likely benign (c.536A\<C, p.Asp179Ala).

###### 

Variants identified in Finnish PAH patients

  Gene     Variant ID                Consequence       Clinical significance   Variant prediction   MAF[1](#tf3-1){ref-type="table-fn"}   Number of patients
  -------- ------------------------- ----------------- ----------------------- -------------------- ------------------------------------- --------------------
  ACVRL1   CM033589                  Missense          Likely benign           Tolerated            0                                     1
  BMPR2    rs137852751               Stop              Pathogenic              Disease-causing      0                                     1
  BMPR2    --                        Frameshift        Pathogenic              Disease-causing      0                                     2
  BMPR2    rs137852752               Missense          Pathogenic              Disease-causing      0.000008134                           1
  BMPR2    rs137852749               Missense          Pathogenic              Disease-causing      0                                     1
  BMPR2    CM010166, COSM209591      Stop              Likely pathogenic       Disease-causing      0                                     1
  BMPR2    rs1061157                 Synonymous        Benign                  Neutral              0.1201                                7
  BMPR2    rs375624016               5′UTR-insertion   Unknown                 Unknown              0                                     3
  BMPR2    rs55722784                Synonymous        Benign                  Neutral              0.01371                               2
  ENG      rs3739817                 Synonymous        Benign                  Neutral              0.09142                               4
  ENG      rs34828244                Synonymous        Benign                  Neutral              0.01042                               2
  ENG      rs36092484                Synonymous        Benign                  Neutral              0.01801                               2
  ENG      rs16930129 (rs11545664)   Synonymous        Benign                  Neutral              0.0983                                4
  ENG      rs35400405                Missense          Benign                  Tolerated            0.04790                               2
  ENG      rs7847860                 Intron            Benign                  Neutral              0.06638                               3

Minor allele frequencies were collected from the ExAC-project data.

In addition, seven variants were detected in *ACVRL1* and *ENG* (Table[3](#tbl3){ref-type="table"}). One patient carried a gene variant featuring a novel missense mutation c.536A\>C (p.Asp179Ala) in a serine and threonine residue-rich region in the *ACVRL1* gene. This *ACVRL1* variant was predicted to be benign by in silico analyses. This patient also tested positive for a pathogenic variant featuring the frameshift mutation in *BMPR2* (Table[3](#tbl3){ref-type="table"}), and therefore the *ACVRL1* variant was classified as likely benign. The variants identified in the *ENG* gene were not considered deleterious (Table[3](#tbl3){ref-type="table"}).

We evaluated the average sequencing depth of the PAH panel for the DNA samples of the 21 Finnish PAH patients by measuring the number of overlapping sequencing reads at each nucleotide position in the 12,638 base target region. The median sequencing depth was 791× and coverage of nucleotides with \>15× sequencing depth was 100%. To demonstrate the sequencing coverage performance of the PAH panel we calculated the percentage of nucleotides exceeding specific sequencing depth threshold (1×--500×) (Fig.[2](#fig02){ref-type="fig"}). To demonstrate further the efficiency of targeted sequencing, the sequencing depth was also evaluated for individual patient samples (Fig.[3](#fig03){ref-type="fig"}) showing that 100% of the target regions were covered with \>15× sequencing depth. Furthermore, we showed that the sequencing depth in the coding exons of the *BMPR2* gene in six PAH patient samples were sequenced in at high depth, as the median coverage was 978× and the coverage of nucleotides with \>15× coverage was 100% (Fig.[4](#fig04){ref-type="fig"}).

![Percentage of target bases covered at different sequencing depths in 21 Finnish PAH patient samples. Results from the sequencing coverage analyses are shown as percentage of targeted bases with \>1×, \>5×, \>10×, \>15×, \>25×, \>50X, \>100×, and until \>500× depth. To generate highly confident genotype calls, \>15× coverage is considered to be enough.](mgg30003-0354-f2){#fig02}

![Sequencing coverage profile of an individual patient sample. The coverage profile of an individual patient shows how OS-Seq PAH panels with median sequencing depth of 662 and covered 100% target regions with \>15× coverage. Coverage depth in *y*-axis shows the average of reads the certain nucleotide is sequenced. Relative nucleotide position is shown in *x*-axis.](mgg30003-0354-f3){#fig03}

![Coverage plot of coding exons of the *BMPR2* gene. The sequencing depth in the coding exons of the *BMPR2* gene in six PAH patient samples were sequenced in at high depths. The median coverage was 978 and coverage of nucleotides with \>15× sequencing depth was 100%.](mgg30003-0354-f4){#fig04}

Discussion
==========

Diagnostics of inherited diseases has entered a new era, in which sophisticated sequencing and bioinformatics reveal pathogenic mutations efficiently. There is estimated to be more than 7000 disorders with Mendelian inheritance and for many of these diseases the molecular genetic mechanism has been discovered. Although individual inherited diseases are rare, together they impose a significant clinical and economical challenge (Costa et al. [@b9]). The increasing realization of genetic underpinnings of inherited diseases has led to diagnostic challenges. Obtaining a complete genetic view of the disease requires high-quality sequencing of large number of genes and genomic regions with explicit clinical relevance and is beyond the scope and capacity of Sanger sequencing applications. At the same time, treatment of inherited diseases in the clinic presumes faster turnaround time and cost-effectiveness from genetic testing. Therefore, long odysseys of mutation exclusion by queuing Sanger sequencing experiments are already outdated in the clinic. Novel technologies have emerged to fulfill the growing clinical demand and to overcome the challenges associated with genetic testing of inherited diseases.

Targeted next-generation sequencing (NGS) is a practical solution for diagnostic-grade and comprehensive analysis of the clinically relevant genomic regions. While sequencing whole genomes or exomes are powerful tools for discovery and research, they fall short meeting the quality requirements of genetic diagnostics. Typical genome with 30× coverage or exome even with 100× coverage contains gaps and regions where sequence information remains unreliable (Meynert et al. [@b23]; Rehm et al. [@b27]; Sims et al. [@b34]). In order to reach consummate clinical genetic interpretation and solid diagnosis, those regions where data are narrow or missing need to be patched with alternative approaches, such as Sanger Sequencing. Necessity of gap-filling makes application of whole-genome sequencing (WGS) and whole-exome sequencing (WES) for genetic diagnostics uneconomical and impractical. Targeted NGS approaches enable cost-efficient, reliable, and high-depth sequencing of clinically relevant genomic regions with complete coverage.

To demonstrate the utility of NGS in the diagnostics of inherited diseases, we have developed an OS-Seq sequencing panel to accurately detect mutations in seven genes that have been implicated in the pathogenesis of PAH. We collected over 900 mutations from literature and existing databases to support the interpretation of the patients' variants. Over 90% of the collected mutations were base substitutions causing missense, nonsense, and splice site mutations or small indels of up to 20 bp that can be identified with NGS (Fig.[1](#fig01){ref-type="fig"}).

The overall performance of our test was high. Sequencing depth and coverage are the main indicators of the performance of NGS. Sequencing depth refers to the number of sequencing reads that pileup at specific nucleotide and is directly associated with the confidence of the genotype call. The average (measured as median) sequencing depth was 791, which illustrates the confidence in calling the genotypes. Sequencing coverage defines the breadth of the genomic area, which has sequencing depth exceeding a specific threshold. Sequencing coverage is related to sensitivity of detecting variants in the target regions (Sims et al. [@b34]). We regarded target regions being covered when exceeding a 15× sequencing depth. It has been demonstrated that a sequencing depth of at least 15× is appropriate for making confident calls, as calling heterozygous variants rarely requires more than 13 overlapping sequence reads (Meynert et al. [@b23]; Sims et al. [@b34]). Sequencing coverage at \>15× depth for our PAH panel was 100% indicating a high sensitivity to detect variants in the target regions.

We analyzed 21 Finnish PAH patients using our novel, targeted OS-Seq panel for PAH. Although the study cohort was small it was able to confirm relatively high incidence (29%) of pathogenic or likely pathogenic variants in *BMPR2* gene among Finnish PAH patients (Table[2](#tbl2){ref-type="table"}). In this cohort, the analysis of other PAH-associated genes did not reveal any other genetic variants considered significant (Table[3](#tbl3){ref-type="table"}), further pinpointing the pivotal role that *BMPR2* has in the pathogenesis of PAH. Importantly, with our OS-Seq approach, we identified all previously detected *BMPR2* mutations and identified two individuals with pathogenic or likely pathogenic *BMPR2* gene variant that were previously missed by Sanger sequencing. In the Sanger method, nonspecific binding of the primers and the formation of DNA secondary structures may cause sequencing errors (Hert et al. [@b12]; Sanger et al. [@b29]). There is also increased risk for human error when interpreting the raw sequencing results due to ambiguities in the capillary electrophoresis readouts. These factors could have caused the failures to identify the two *BMPR2* mutations in the primary study (Sankelo et al. [@b30]).

*ACVRL1* or *ENG* mutations are often found in PAH patients with family history of hereditary hemorrhagic telangiectasia (HHT) (Harrison et al. [@b11]). As none of the studied Finnish PAH patients manifested clear HHT-disease, it was not surprising that the analysis of *ACVRL1* and *ENG* did not identify any pathogenic variants (Table[3](#tbl3){ref-type="table"}). The patient with the variant in the *ACVRL1* gene (c.536A\>C, p.Asp179Ala) also carried a pathogenic deletion in the *BMPR2* gene (c.1376_1377delGA, p.Arg459ThrfsX11) (Table[2](#tbl2){ref-type="table"}). Interestingly, this pathogenic *BMPR2* variant resulting a frameshift was missed in previous study (Sankelo et al. [@b30]) using Sanger sequencing and the *ACVRL1* mutation was considered a potential cause for PAH although the patient lacked clear symptoms associated with HHT. As the patient is carrying a *BMPR2* variant resulting a deletion and is considered to be pathogenic, we suggest that it is unlikely that this *ACVRL1* variant is an independent disease-causing mutation. The identified *ENG* gene variant, featuring a missense mutation (c.14C\>T, p.Thr5Met; rs35400405), from two patients is interesting as it leads to the replacement of threonine by methionine resulting a suppression of *ENG* expression (Bourdeau et al. [@b4]). Despite its direct effects on protein (Bourdeau et al. [@b4]) it is predicted to be non-disease causing as the allele is common in general population (MAF 0.04790) (Table[3](#tbl3){ref-type="table"}).

Characterization of mutations in PAH enables establishing estimates on prognosis. *BMPR2* mutations are associated with an earlier age of disease onset, regardless of familial history, and with more severe disease phenotype. Furthermore, patients with *BMPR2* mutations are less likely to response to vasodilators than mutation-negative patients (Austin et al. [@b2]; Ma and Chung [@b17]). PAH patients carrying mutations in *ACVRL1* gene show more rapid disease progression than patients with *BMPR2* mutations, despite responding to vasodilators at the time of diagnosis (Girerd et al. [@b10]). In addition, patients identified with *BMPR2* and *ACVRL1* mutations have a shorter survival time or earlier need for lung transplantation (Austin et al. [@b2]; Chida et al. [@b8]; Girerd et al. [@b10]; Ma and Chung [@b17]). The study of Austin and coworkers in 2009 reported that patients with missense mutations in *BMPR2* gene are diagnosed in much younger age and seem to have a significantly shorter survival time compared to patients with truncating mutations (Austin et al. [@b2]). In 2012, Liu with colleagues reported male *BMPR2* mutation carriers had a worse prognosis compared to female mutation carriers (Liu et al. [@b16]). Pediatric PAH patients, with or without *BMPR2* mutation, show distinct response to vasodilators than adults, and are more likely to associate with other genetic syndromes (Ma and Chung [@b17]).

Utilization of novel targeted OS-Seq approach increases the diagnostic efficacy by offering better quality and faster turnaround time. As shown in this study, OS-Seq technology proved to be a practical and effective tool for genetic profiling of Finnish patients with PAH. As genetic testing is increasingly applied in clinical practice, it is important to acknowledge the requirements of quality and performance of available genetic tests. Diagnostic-grade deep sequencing with 100% covered target base pairs is becoming a standard requirement in today's clinical genetic testing. The high incidence of disease mutations in patients with IPAH and HPAH and elevated estimates of disease penetrance are supporting the utilization of genetic testing as routine procedure in the evaluation of patients with IPAH or HPAH. As in other hereditary cardiovascular diseases genetic diagnosis can significantly rationalize the risk stratification and follow-up strategies in the family and can have impact in estimating index patient's prognosis. New sequencing strategies and bioinformatics tools are enabling diagnostics with faster turnaround times and decreased cost.
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